Weis Markets, Inc. (WMK) SEC Filings & Earnings Calls
EquiReason read 13 Weis Markets, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-06 — Weis Markets reported Q2 2026 results with 4.6% sales growth, gross margin expansion, but lower net income due to higher operating expenses; no explicit beat or miss versus expecta.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.0B
- P/E TTM
- 19.7
- Dividend yield
- 1.7%
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
6 Aug 202610-QWeis Markets reported Q2 2026 results with 4.6% sales growth, gross margin expansion, but lower net income due to higher operating expenses; no explicit beat or miss versus expectations stated.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $1.27B | +5% y/y |
| Net income · Q2-2026 | $23M | -10% y/y |
| Operating cash flow · H1-2026 | $95M | +55% y/y |
Risks flagged
Operating expense inflation
“Operating, general and administrative expenses increased 8.3% in Q2 2026 vs Q2 2025, driven by higher employee costs, utilities, and outside services.”
Competitive pressure
“Management acknowledges some competitors have greater financial resources and could use these resources to take measures which could adversely affect the Company’s competitive position.”
4 Aug 20268-K · 2.02Total revenue $1.28B (+5% y/y); Net sales $1.27B (+5% y/y); Comparable store sales 2.3earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q2-2026 | $1.28B | +5% y/y |
| Net sales · Q2-2026 | $1.27B | +5% y/y |
| Comparable store sales · Q2-2026 | 2.3% | |
| Net income · Q2-2026 | $23M | -10% y/y |
| Earnings per share · Q2-2026 | $0.92 | -4% y/y |
| Gross profit on sales · Q2-2026 | $328M | +7% y/y |
| Income from operations · Q2-2026 | $29M | -4% y/y |
| Cash dividends per share · Q2-2026 | $0.34 | 0% y/y |
Risks flagged
Pharmacy revenue headwind from Inflation Reduction Act Medicare maximum fair price provisions.
“Pharmacy revenue growth unfavorably impacted by approximately $10.71 million in Q2 and $18.19 million YTD from IRA pricing headwinds.”
Customers focused on affordability, requiring increased promotional investment.
“CEO: 'Customers remain focused on affordability and value... we have increased our investment in promotions and targeted loyalty marketing.'”
7 May 202610-QTotal revenue $1.26B (+5% y/y); Net income $28M (+42% y/y); Gross profit margin 26.4open
Figures in the filing · each found in the filing text
| Total revenue · Q1-2026 | $1.26B | +5% y/y |
| Net income · Q1-2026 | $28M | +43% y/y |
| Gross profit margin · Q1-2026 | 26.4% | |
| Operating cash flow · Q1-2026 | $30M | +523% y/y |
| Comparable store sales (including fuel) · Q1-2026 | 2.1% | |
| Comparable store sales (excluding fuel) · Q1-2026 | 1.2% | |
| Capital expenditures · Q1-2026 | $39M | +19% y/y |
| Cash dividends per share · Q1-2026 | $0.34 | 0% y/y |
Risks flagged
Material weakness in internal controls over financial reporting
“The Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were not effective for the periods covered through March 28, 2026.” · word for word
Inventory overstatement and restatement exposure
“The material weakness resulted in an overstatement of inventory in our previously issued financial statements.” · word for word
Increased operating expenses
“Operating, general and administrative expenses increased 6.5% to $294.5 million, driven by higher employee expenses, outside services and repairs, and utilities.”
6 May 20268-K · 2.02Total revenue $1.26B (+5% y/y); Comparable store sales excluding fuel 1.2; Net income $28M (+42% y/y)earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q1-2026 | $1.26B | +5% y/y |
| Comparable store sales excluding fuel · Q1-2026 | 1.2% | |
| Net income · Q1-2026 | $28M | +43% y/y |
| Earnings per share · Q1-2026 | $1.13 | +55% y/y |
| Cash dividends per share · Q1-2026 | $0.34 | 0% y/y |
Risks flagged
Pharmacy revenue impacted by Inflation Reduction Act pricing headwinds.
“Pharmacy revenue growth was unfavorably impacted by approximately $7.48 million due to pricing headwinds associated with the Inflation Reduction Act Medicare maximum fair price (MFP) provisions” · word for word
13 Mar 20268-K · 2.02Total revenue $4.96B (+4% y/y); Net income $94M (-12% y/y); Earnings per share $3.65 (-7% y/y)earningsopen
Figures in the filing · each found in the filing text
| Total revenue · FY2025 | $4.96B | +4% y/y |
| Net income · FY2025 | $94M | -12% y/y |
| Earnings per share · FY2025 | $3.65 | -7% y/y |
| Comparable store sales excluding fuel · FY2025 | 2.1% | |
| E-commerce sales growth · FY2025 | 21.0% | |
| Quarterly cash dividend per share · Q1-2026 | $0.34 | 0% y/y |
Risks flagged
Restatement of historical financial statements due to inventory overstatement introduces accounting and litigation risk.
“the impact to, and associated restatement of, its historical financial statements related to the incorrect recording of certain overstated inventory amounts” · word for word
Cautious consumer spending environment may pressure future sales growth.
“Despite ongoing cautious customer spending” · word for word
12 Mar 202610-KStore count 202 (+2% y/y)open
Figures in the filing · each found in the filing text
| Store count · FY2025 | 202 | +2% y/y |
Risks flagged
Inventory restatement and material weakness
“This restatement related to the Company’s overstatement of certain inventory amounts related to a single meat product manufacturing plant.” · word for word
Tariff risk on input costs
“In 2025, the United States and foreign governments imposed tariffs on specific goods imported from certain trading partners. These current or proposed tariffs could result in an adverse and uncertain economic environment.” · word for word
Litigation risk from former COO
“Kurt Schertle, the former Chief Operating Officer and Secretary of the Company, filed the claim... The Company does not believe the demand received on November 4, 2025 has any merit and will vigorously dispute any claim for payment.” · word for word
12 Mar 2026DEF 14AProxy statement discloses inventory restatement triggering $1.28M executive clawback, share repurchase from estate, and compensation structure tied to net sales and MROIC.open
Figures in the filing · each found in the filing text
| Net Sales · FY2025 | $4.94B | +3% y/y |
| Net Income · FY2025 | $94M | -12% y/y |
| Total Shareholder Return (Cumulative $100 Investment) · FY2025 | $150.00 | -4% y/y |
| Peer Group Total Shareholder Return (Cumulative $100 Investment) · FY2025 | $225.00 | +8% y/y |
Risks flagged
Inventory Restatement and Internal Control Weakness
“On March 12, 2026 , the Company filed its Form 10-K for the fiscal year ended December 27, 2025 in which the Company restated certain prior financial statements due to an overstatement of certain inventory amounts related to a single meat product manufacturing plant.” · word for word
Controlled Company Governance Risk
“The Weis family, consisting of Jonathan H. Weis, Chairman, President and Chief Executive Officer, the Estate of Patricia G. Ross Weis, Jennifer Weis, Colleen Ross Weis, Ellen W. P. Wasserman, Kathryn J. Zox, Thomas H. Platz, James A. Platz and EKTJ Management LLC control approximately 61% of the voting power of the Company.” · word for word
Low Trading Volume and Stock Price Disconnect from Performance
“As is common with controlled companies, the Company has a low trading volume. Due to such low trading volume and for other reasons, historically the Company's stock price has not been driven by financial results but rather by general market fluctuations and dividend return.” · word for word
25 Feb 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen
Risks flagged
Inventory overstatement restatement risk; potential material weakness in internal controls.
“Incorrect recording of certain overstated inventory amounts; restatement of historical financial statements.” · word for word
20 Feb 20268-K · 4.02Inventory overstatement estimate $22Mopen
Figures in the filing · each found in the filing text
| Inventory overstatement estimate · meat manufacturing plant · Q3-2025 | $22M |
Risks flagged
Material restatement of financial statements for FY2022-2024 and Q1-Q3 2025 due to inventory overstatement.
“concluded that the Company's previously issued audited consolidated financial statements ... should no longer be relied upon” · word for word
Potential material weakness in internal controls over financial reporting; SEC and legal exposure.
“The Company is also evaluating the impact of this matter on internal controls over financials reporting.” · word for word
Restatement timeline uncertain; may delay future filings and impact lender/covenant compliance.
“The Company is unable at this time to estimate the timing for completion of the filing of any restatements” · word for word
6 Nov 202510-QWeis Markets reported Q3 2025 results with net sales up 4.4% but net income down 29.4% due to higher operating expenses.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q3-2025 | $1.24B | +4% y/y |
| Net income · Q3-2025 | $18M | -29% y/y |
| Comparable store sales (individual year) · Q3-2025 | 2.5% | |
| Gross profit margin · Q3-2025 | 24.9% | |
| Operating margin · Q3-2025 | 1.8% | |
| Capital expenditures · 39W-2025 | $152M | +41% y/y |
| Cash and cash equivalents · Q3-2025 | $55M | |
| Pharmacy net sales · Pharmacy · Q3-2025 | $178M | +15% y/y |
Risks flagged
Operating expense pressure
“Operating, general and administrative expenses increased 7.9% in Q3 2025 vs prior year, outpacing sales growth.”
Cash depletion
“Cash and cash equivalents decreased from $190.3M to $54.7M due to share repurchase and capex.”
4 Nov 20258-K · 2.02Net sales $1.24B (+4% y/y); Comparable store sales excluding fuel 2.5; Net income $18M (-29% y/y)earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q3-2025 | $1.24B | +4% y/y |
| Comparable store sales excluding fuel · Q3-2025 | 2.5% | |
| Net income · Q3-2025 | $18M | -29% y/y |
| Earnings per share · Q3-2025 | $0.74 | -23% y/y |
| Gross profit on sales · Q3-2025 | $309M | +5% y/y |
Risks flagged
Earnings miss: net income down 29.4% due to higher costs and prior-year gain.
“Net income totaled $18.23 million compared to $25.84 million in 2024, down 29.4 percent.” · word for word
Cautious consumer spending and macroeconomic uncertainty.
“Despite ongoing cautious consumer spending and macroeconomic uncertainty in the third quarter.” · word for word
Weis Markets, Inc. — questions
- What did Weis Markets, Inc. file recently?
- 13 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-06 — Weis Markets reported Q2 2026 results with 4.6% sales growth, gross margin expansion, but lower net income due to higher operating expenses; no explicit beat or miss versus expectations stated.
Every figure on this page comes from Weis Markets, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.